
1. IDENTIFICATION

Product Name	EQUIMAX® (ivermectin 1.87%/praziquantel 14.03%) Paste
Recommended use of the chemical and restrictions on use	
Identified uses	Worm control for horses and ponies
Restrictions on Use	For veterinary use, Not for human use
Company Identification	Virbac AH, Inc. P.O. Box 162059 Fort Worth, Texas 76161 (800) 338-3659
Customer Information Number	
Emergency Telephone Number	
CHEMTREC Number	(800) 424-9300
Other Emergency Number:	Human Toll-free 833-224-2009 Animal Toll-free 833-224-2013
Issue Date	January 9, 2026
Supersedes Date	December 21, 2025

Safety Data Sheet prepared in accordance with OSHA's Hazard Communication Standard (29 CFR 1910.1200-2024) and the Globally Harmonized System of Classification and Labelling of Chemicals (GHS).

2. HAZARD IDENTIFICATION

Hazard Classification
 Acute Toxicity (oral) – Category 4
 Acute Aquatic Toxicity – Category 1 (not an OSHA recognized hazard)

Label Elements
 Hazard Symbols



Signal Word: WARNING

Hazard Statements
 Harmful if swallowed.
 Very toxic to aquatic life.

2. HAZARD IDENTIFICATION

Precautionary Statements
Prevention

Wash hands thoroughly after handling.
 Do not eat, drink or smoke while using this product.
 Avoid release to the environment.

Response

If swallowed: Call a poison center or doctor if you feel unwell. Rinse mouth.
 Collect spillage.

Disposal

Dispose of contents/container in accordance with local regulation.

Other Hazards including hazards associated with change in form or chemical reaction.

None known.

Specific Concentration Limits

The values listed below represent the percentages of ingredients of unknown toxicity.

Acute oral toxicity	0%
Acute dermal toxicity	0%
Acute inhalation toxicity	0%
Acute aquatic toxicity	0%

3. COMPOSITION/INFORMATION ON INGREDIENTS

Synonyms:

This product is a mixture.

Component Name	CAS Number	Concentration*
Praziquantel	55268-74-1	14.03%
Ivermectin	70288-86-7	1.87%
Titanium Dioxide	13463-67-7	1-5%*

*Exact concentration withheld as trade secret.

4. FIRST- AID MEASURES

Description of necessary first-aid measures**Eyes**

Immediately flood the eye with plenty of water for several minutes, holding the eye open. Obtain medical attention if symptoms persist.

Skin

Wash skin thoroughly with soap and water. Obtain medical attention if symptoms persist.

Ingestion

Rinse mouth with water. Call a poison control center or doctor for treatment advice. Do not induce vomiting unless told to do so by a poison control center or doctor. Do not give anything by mouth to an unconscious person.

Inhalation

Remove person to fresh air. Seek medical attention if symptoms persist.

Most important symptoms/effects, acute and delayed

Aside from the information found under Description of necessary first aid measures (above) and Indication of immediate medical attention and special treatment needed, no additional symptoms and effects are anticipated.

Indication of immediate medical attention and special treatment needed**Notes to Physicians**

Treat symptomatically. No specific antidote.

5. FIRE - FIGHTING MEASURES

Extinguishing Media

Use foam, dry chemical or carbon dioxide. Keep containers and surroundings cool with water spray.

Unusual Fire and Explosion Hazards

Can release hazardous vapors during a fire. Do not release contaminated fire water to the environment.

Protective Equipment for Fire-Fighting

Wear full protective clothing and self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures

Wear appropriate protective clothing.

Environmental Precautions

Prevent the material from entering drains or watercourses.

Methods and materials for containment and cleaning up

Wipe up and transfer into suitable containers for recovery or disposal.

7. HANDLING AND STORAGE

Precautions for safe handling

Wear appropriate protective clothing. Do not eat, drink, or smoke during use of product. Avoid contact with eyes, skin and clothing. Wash hands after use.

Conditions for safe storage

Store in original container at room temperature 25°C/77°F with excursions permitted between 59°F and 85°F (15°C - 30°C). Keep out of sunlight. Store away from children and pets.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure limits are listed below, if they exist.

Praziquantel

None established

Ivermectin

None established

Titanium Dioxide

15 mg/m³ TWA OSHA PEL

.25 mg/m³ (respirable, finescale) TWA ACGIH TLV

Appropriate engineering controls

Engineering methods to prevent or control exposure are preferred. Methods include process or personnel enclosure, mechanical ventilation (dilution and local exhaust), and control of process conditions. No specific measures required for the normal use of this product.

Individual protection measures
Respiratory Protection

Finished product does not require respiratory protection under normal conditions of use. Wear respiratory protection if there is a risk of exposure in enclosed areas. A NIOSH approved respirator should be worn. The specific respirator selected must be based on the airborne concentration found in the workplace and must not exceed the working limits of the respirator.

Skin Protection

Impervious gloves recommended

Eye/Face Protection

None normally required. Safety glasses or goggles if needed to avoid eye contact.

Body Protection

Normal work wear.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Physical State Solid (paste)

Color White

Odor None

Odor Threshold Not applicable

pH Not applicable

Density No data available

Boiling Range/Point (°C/F) Not applicable

Melting Point (°C/F) Not applicable

Flash Point (PMCC) (°C/F) Not flammable

Vapor Pressure Not applicable

Particle Characteristics No data available

Solubility in Water No data available

Relative Vapor Density (Air = 1) Not applicable

VOC Not applicable

Partition coefficient (n-octanol/water) Not applicable

Kinematic Viscosity Not applicable

Auto-ignition Temperature No data available

Decomposition Temperature No data available

Upper explosive limit No data available

Lower explosive limit No data available

Flammability Not flammable

10. STABILITY AND REACTIVITY

Reactivity

Product is considered stable.

Chemical Stability

Stable under normal conditions.

Possibility of hazardous reactions

None known. Hazardous polymerization will not occur.

Conditions to Avoid

Sunlight - high temperatures - contact with incompatible materials

Incompatible Materials

Strong oxidizing agents

Hazardous Decomposition Products

Thermal decomposition- Oxides of carbon, Organic compounds

11. TOXICOLOGICAL INFORMATION

Acute ToxicityIvermectin

Oral LD50 (rat) 10 mg/kg

Oral LD50 (mouse) 11.6 mg/kg

Dermal LD50 (rabbit) 406 mg/kg

Inhalation LC50 (rat) >5.11 mg/m³/4Hr (dust – maximum attainable concentration)

Praziquantel

Oral LD50 (rat) 2840 mg/kg

Dermal LD50 (rat) >2000 mg/kg

Specific Target Organ Toxicity (STOT) – single exposure: Not classified

Ivermectin: At high doses in humans and animals vomiting, tachycardia, blood pressure fluctuation, CNS effects (somnolence, ataxia) and visual disturbances have been observed. Higher doses may cause death due to respiratory depression.

Praziquantel: Acute overexposure (ingestion) may cause dizziness, headache, drowsiness, malaise, abdominal pain.

Specific Target Organ Toxicity (STOT) – repeat exposure: Not classified

Ivermectin: No data available

Praziquantel: Chronic overexposure may cause nausea, lethargy, diarrhea, itching, fever and rash.

Serious Eye damage/Irritation: Not classified

Ivermectin: Slightly irritating to eyes in rabbit tests.

Praziquantel: Not irritating to eyes in rabbit studies.

Skin Corrosion/Irritation: Not classified

Ivermectin: Non-irritating in animal studies.

Praziquantel: Not irritating to skin in rabbit studies.

Respiratory or Skin Sensitization: Not classified

Ivermectin: Hypersensitivity reactions have been reported in humans.

Praziquantel: Not sensitizing to skin in guinea pig study.

Carcinogenicity: Not classified

Titanium Dioxide: IARC Overall Evaluation is 2B (Possibly carcinogenic to humans) IARC evaluation guidelines consider the generation of tumors, in 2 different studies within the same animal species, to be adequate criteria for an assessment of sufficient evidence. The conclusions of several epidemiology studies on more than 20000 TiO₂ industry workers in Europe and the USA did not suggest a

carcinogenic effect of TiO₂ dust on the human lung. Mortality from other chronic diseases, including other respiratory diseases, was also not associated with exposure to TiO₂ dust. Based upon these studies, titanium dioxide is not expected to cause lung cancer or chronic respiratory diseases in humans at concentrations experienced in the workplace. The titanium dioxide is bound in product matrix and no inhalation exposure can occur.

Praziquantel: Long term studies in rats and golden hamsters did not reveal any carcinogenic effect

Germ Cell Mutagenicity: Not classified

Ivermectin: Negative in the AMES Assay, and in a mouse lymphoma mutation assay. In addition, it did not induce unscheduled DNA synthesis in a human fibroblast cell culture, suggesting that it does not damage DNA.

Praziquantel: Negative results for in vivo and in vitro animal studies.

Reproductive Toxicity: Not classified

Ivermectin: Teratogenic in rats, rabbit and mice at or near materno-toxic dose levels. The abnormalities are limited mainly to cleft palate.

Praziquantel: Studies in rats and rabbits have shown no evidence of impaired fertility or harm to the fetus. An increase of the abortion rate was found in rats at three times the single human therapeutic dose.

Aspiration Hazard

Not classified as an aspiration hazard.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Ivermectin:

LC₅₀ (Trout) 0.0032 mg/l 96hr

EC₅₀ (Daphnia magna) 0.00036 mg/l 48hr

Mobility in soil

Ivermectin: Ivermectin is metabolized in the soil. Water solubility is limited and it binds to soil very tightly. It does not bioconcentrate in fish and is not taken up from soil into plants.

Persistence/Degradability

Ivermectin: Slow biodegradation. Photodegrades rapidly.

Bioaccumulative Potential

Ivermectin: Not bioaccumulative

Other adverse effects

None known

13. DISPOSAL CONSIDERATIONS

Disposal Methods

Dispose of in accordance with all applicable local and national regulations.

14. TRANSPORT INFORMATION

DOT CFR 172.101 Data

Not regulated

IMDG/IATA Data:

UN Proper Shipping Name	Environmentally Hazardous Substance (ivermectin)
UN Class	9
UN Number	UN3082
UN Packaging Group	III

Note: Single packages and inner packagings of combination packages containing ≤ 5 L/kg are excepted from regulation.

15. REGULATORY INFORMATION

United States TSCA Inventory

This product is excluded from the US EPA Toxic Substance Control Act and is regulated under the Food, Drug and Cosmetic Act.

SARA Title III Sect. 311/312 Categorization

Refer to Section 2 for the OSHA Hazard Classification.

SARA Title III Sect. 313

This product does not contain any chemicals listed in Section 313 at or above de minimis concentrations.

Canada DSL

All ingredients have not been verified for listing on the Domestic Substance List (DSL).

16. OTHER INFORMATION

Legend

ACGIH: American Conference of Governmental Industrial Hygienists
BOD: Biological Oxygen Demand
CAS#: Chemical Abstracts Service Number
FIFRA: Federal Insecticide, Fungicide and Rodenticide Act
IARC: International Agency for Research on Cancer
LC50: Lethal Concentration 50%
LD50: Lethal Dose 50%
N/A: Denotes no applicable information found or available
NTP: National Toxicology Program
NOAEL: No Observed Adverse Effect Level
OSHA: Occupational Safety and Health Administration
PEL: Permissible Exposure Limit
STEL: Short Term Exposure Limit
TLV: Threshold Limit Value
TSCA: Toxic Substance Control Act

Revision Date: January 9, 2026

Replaces: March 3, 2020

Changes made: Sections, 2, 8, 9, 11, 12, 14

Information Source and References

This SDS is prepared by Hazard Communication Specialists based on information provided by internal company references.

EQUIMAX® is a registered trademark of Virbac Corporation



SAFETY DATA SHEET
EQUIMAX®
(ivermectin 1.87%/praziquantel 14.03%) Paste

The information and recommendations presented in this SDS are based on sources believed to be accurate. Neither Virbac AH, Inc. nor any of its affiliated companies assumes any liability for the accuracy or completeness of this information. It is the user's responsibility to determine the suitability of the material for their particular purposes. In particular, we make **NO WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED**, with respect to such information, and we assume no liability resulting from its use. Users should ensure that any use or disposal of the material is in accordance with applicable Federal, State, and local laws and regulations.
